- Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries.
- ETFs: BIB, GRX, THW, BME, BIS, IXJ, ARKG, IDNA, XLV, PJP, XBI, IHE, XPH
- Takeda (TAK -0.3%), Bausch Health Companies (BHC -4.4%), Roche (OTCQX:RHHBY -1.9%), AbbVie (ABBV -1%), Allergan (AGN -0.3%), AstraZeneca (AZN -1.8%), Bristol-Myers Squibb (BMY -3.5%), GlaxoSmithKline (GSK -0.6%), Johnson & Johnson (JNJ -1.1%), Eli Lilly (LLY -4.4%), Merck (MRK -4.9%), Novo Nordisk (NVO -3%), Novartis (NVS -1.5%), Pfizer (PFE -2.7%), Teva Pharmaceutical Industries (TEVA -2.5%)
Big Biopharma in the red as investors wait for Trump's drug price plan
ProShares Ultra Nasdaq Biotechnology ETF (BIB), GRX, THW, BME, BIS, IXJ, ARKG, IDNA, XLV, PJP, XBI, IHE, XPH, TAK Stock, BHC Stock, RHHBY Stock, ABBV Stock, AGN Stock, AZN Stock, BMY Stock, GSK Stock, JNJ Stock, LLY Stock, MRK Stock, NVO Stock, NVS Stock, PFE Stock, TEVA Stock, BHC:CA StockDouglas W. House, 141 Comments